Hepatosplenic T-cell lymphoma in a patient with Crohn's disease

被引:21
作者
Beigel, Florian [1 ]
Juergens, Matthias [1 ]
Tillack, Cornelia [1 ]
Subklewe, Marion [2 ]
Mayr, Doris [3 ]
Goeke, Burkhard [1 ]
Brand, Stephan [1 ]
Ochsenkuehn, Thomas [1 ]
机构
[1] Univ Hosp Munich Grosshadern, Dept Med 2, D-81377 Munich, Germany
[2] Univ Hosp Munich Grosshadern, Dept Med 3, D-81377 Munich, Germany
[3] Univ Hosp Munich Grosshadern, Dept Pathol, D-81377 Munich, Germany
关键词
INFLAMMATORY-BOWEL-DISEASE; GAMMA-DELTA; RANDOMIZED-TRIAL; INFLIXIMAB; MAINTENANCE; RISK;
D O I
10.1038/nrgastro.2009.87
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. a 58-year-old man who had a 35-year history of Crohn's disease presented to our IBD center with a disease flare, pararectal fistulas and abscess formation. the patient had previously undergone ileocolic resection for a stenosis and his abscesses had been treated by surgical drainage. He had been taking azathioprine therapy for approximately 5.5 years and had received high-dose steroids. He had also previously taken metronidazole and antihypertensive medications. Investigations. Physical examination, laboratory investigations including hemoglobin levels and white blood cell counts, genetic testing, CT, bone-marrow biopsy, immunophenotyping by fluorescence-activated cell sorting, polymerase chain reaction analyses, fluorescence in situ hybridization, sputum culture and diagnostic splenectomy. Diagnosis. Hepatosplenic T-cell lymphoma. Management. splenectomy, antibiotic therapy and chemotherapy with cyclophosphamide.
引用
收藏
页码:433 / 436
页数:4
相关论文
共 17 条
  • [1] In vitro and in vivo effects of 2′-deoxycoformycin (Pentostatin) on tumour cells from human γδ+ T-cell malignancies
    Aldinucci, D
    Poletto, D
    Zagonel, V
    Rupolo, M
    Degan, M
    Nanni, P
    Gattei, V
    Pinto, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (01) : 188 - 196
  • [2] Beaugerie L, 2008, GASTROENTEROLOGY, V134, pA116
  • [3] Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome:: report on a series of 21 patients
    Belhadj, K
    Reyes, F
    Farcet, JP
    Tilly, H
    Bastard, C
    Angonin, R
    Deconinck, E
    Charlotte, F
    Leblond, V
    Labouyrie, E
    Lederlin, P
    Emile, JF
    Delmas-Marsalet, A
    Arnulf, B
    Zafrani, ES
    Gaulard, P
    [J]. BLOOD, 2003, 102 (13) : 4261 - 4269
  • [4] FARCET JP, 1990, BLOOD, V75, P2213
  • [5] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Hanauer, SB
    Feagan, BG
    Lichtenstein, GR
    Mayer, LF
    Schreiber, S
    Colombel, JF
    Rachmilewitz, D
    Wolf, DC
    Olson, A
    Bao, WH
    Rutgeerts, P
    [J]. LANCET, 2002, 359 (9317) : 1541 - 1549
  • [6] HUMPHREYS MR, 2008, LEUKEMIA LYMPHOMA, V29, P1
  • [7] Jaffe E.S., 2001, PATHOLOGY GENETICS T, V3
  • [8] Jonveaux P, 1996, LEUKEMIA, V10, P1453
  • [9] Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
    Kandiel, A
    Fraser, AG
    Korelitz, BI
    Brensinger, C
    Lewis, JD
    [J]. GUT, 2005, 54 (08) : 1121 - 1125
  • [10] The serine protease granzyme M is preferentially expressed in NK-cell, γδ T-cell, and intestinal T-cell lymphomas:: evidence of origin from lymphocytes involved in innate immunity
    Krenacs, L
    Smyth, MJ
    Bagdi, E
    Krenacs, T
    Kopper, L
    Rudiger, T
    Zettl, A
    Muller-Hermelink, HK
    Jaffe, ES
    Raffeld, M
    [J]. BLOOD, 2003, 101 (09) : 3590 - 3593